Peripheral serotonin, synthesized by tryptophan hydroxylase-1 (TPH 1 ), has been shown to play a key role in several physiological functions. Recently, controversy has emerged about whether peripheral serotonin has any effect on bone density and remodeling. We therefore decided to investigate in detail bone remodeling in growing and mature TPH 1 knockout mice (TPH 1
TPH 1
−/− in the presence of macrophage colony-stimulating factor and receptor activator for NF-KB ligand (RANKL) displayed fewer osteoclasts, and the decreased differentiation could be rescued by adding serotonin. Our data also provide evidence that in the presence of RANKL, osteoclast precursors express TPH 1 and synthesize serotonin. Furthermore, pharmacological inhibition of serotonin receptor 1B with SB224289, and of receptor 2A with ketanserin, also reduced the number of osteoclasts. Our findings reveal that serotonin has an important local action in bone, as it can amplify the effect of RANKL on osteoclastogenesis.
neuromediator | osteopetrosis B one remodeling is a highly integrated process that continuously renews mineralized tissue throughout the skeleton to assure harmonious growth, maintenance, and repair throughout the lifespan of the individual. It couples the resorption of mineralized bone by osteoclasts and bone formation by osteoblasts. Osteoblasts originate from mesenchymal stem cells (1) , and osteoclasts are multinucleated cells derived from a hematopoietic precursor of the monocyte macrophage lineage (2) . Dysregulation of osteoclast function or differentiation results in an osteopetrotic phenotype, with a marked increase in bone density. In contrast, increased bone resorption is associated with bone loss in diseases such as osteoporosis, arthritis, and metastatic bone lesions. Molecular communication between osteoblasts and osteoclasts is required to regulate the commitment, proliferation, and differentiation of bone cell precursors. The main osteoclastogenic signals are the receptor activator for NF-KB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF), both of which are cytokines secreted by osteoblasts (3) .
Serotonin, or 5-hydroxytryptamine (5-HT), mediates a wide range of central functions, such as mood, behavior, sleep, blood pressure, and thermoregulation (4) . Peripherally, serotonin is involved mainly in the regulation of vascular and heart functions (5, 6) and in gastrointestinal mobility (7) . The diverse actions of 5-HT result from the presence of multiple 5-HT receptors (5-HTRs). These various different receptors have been divided into seven classes (5-HT 1 R to 5-HT 7 R) (8) . Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in 5-HT biosynthesis. There are two isoforms of this enzyme: TPH 2 is mainly expressed in brain, and TPH 1 is expressed elsewhere in the body (9, 10) . 5-HT is produced by TPH 1 in the enterochromaffin cells of the gastrointestinal tract and accumulates in platelet-dense granules, which constitute the body's main 5-HT reservoir (11) . The action of serotonin is mainly paracrine and involves a complex action through its transporter and different receptors (4) . In the periphery, although the main site of serotonin synthesis is the enterochromaffin cells of the gut, TPH 1 expression and local serotonin synthesis have been shown to have a functional role in the cardiovascular system (12) , mammary gland (13) , and pancreas (14) .
The action of serotonin in bone has recently been the subject of controversy. Using specific invalidation of TPH 1 in different murine tissues, Yadav et al. reported that serotonin produced in the gut decreased bone formation via the 5-HT 1B receptor that they observed in osteoblasts (15) . This group also published data showing that the pharmacological inhibition of TPH 1 was able to prevent bone loss in ovariectomized rodents (16) . In contrast, Cui et al. observed no change in bone density measured by dual-energy X-ray absorptiometry in TPH 1 −/− mice 4 and 6 mo of age (17) . However, in these studies, the main point of interest was whether changes in serotonin could be responsible for the bone phenotype of LRP5 −/− mice (18) . In brief, data from the Karsenty group suggest that the bone formation defect in LRP5 −/− mice is not cell-autonomous but is induced by an increase in the serotonin level in serum (15), whereas Cui et al., using osteoblast-and osteocyte-specific knockout and knockins of the LRP5 mutation that induces a high and low bone mass phenotype in humans, claimed that LRP5 has a direct effect in the osteoblast without any change in whole-blood serotonin (17) .
In these two conflicting studies, only a putative endocrine action of serotonin on bone was explored. However, various data about the action of serotonin on bone had previously been reported in vivo and in vitro. Osteoblasts were found to express the 5-HT transporter (SERT) and various serotonin receptors (19, 20) , and we have shown that invalidation of the 5-HT 2B receptor induced decreased bone formation in aging mice (21) . The lack of SERT also induces a decrease in bone accrual during growth in mice (22) .
To reevaluate these controversial findings, we decided to study bone remodeling in TPH 1 −/− mice while they were growing and at maturity. Our findings show that serotonin deficiency is responsible for a decrease in osteoclastic differentiation both during growth and at maturity. During growth, this decrease is responsible for an increase in bone density that resolves in adult animals due to the subsequent decrease in bone formation. We identified 5-HT as a regulator of osteoclast differentiation and function both in vivo and ex vivo. Furthermore, we show that osteoclast precursors are able to synthesize serotonin, and that the decrease in osteoclastic resorption is cell-autonomous in TPH 1 −/− mice.
Results
Bone Density and Formation Decrease from Growth to Maturity in TPH 1 −/− Mice. To determine bone phenotype, the bone mineral density (BMD) of male TPH 1 −/− and WT mice was assessed at 6 and 16 wk. At 6 wk, while they were still growing, TPH 1 −/− mice displayed higher BMD than WT mice in total body (+22%), at the femur (+17%), and at the vertebrae (+15%). In both genotypes, BMD increased significantly from 6 to 16 wk. However, the increase was lower in TPH 1 −/− mice than in WT mice, and BMD was not significantly different in mature WT and TPH 1 −/− mice at 16 wk (Table 1) . To analyze the bone phenotype further, we carried out bone histomorphometry in 6-and 16-wk-old WT and TPH 1 −/− mice. A higher trabecular bone volume to total bone volume ratio (BV/TV) (+67%) was observed in TPH 1 −/− mice than in WT mice at 6 wk. The BV/TV measured in mature TPH 1 −/− mice at 16 wk was no longer significantly different from WT values, and was dramatically lower than that of BV/TV at 6 wk of age (Table 1) . To find out whether bone formation was affected by TPH 1 invalidation, we measured osteoblast surface per bone surface and the dynamic parameter of bone formation [bone formation rate (BFR); per bone surface (BS)] ( Fig. 1 A  and B) and quantified serum osteocalcin, a biochemical marker of bone formation (Fig. 1C) Fig.  2A , the osteoclastic surfaces at the femoral metaphysis were lower in TPH 1 −/− mice than in WT at 6 wk (−44.4%), and this phenotype persisted at 16 wk (−34.8%). Furthermore, the osteoclast number was also reduced at both ages (Fig. 2B) . We next measured urinary D-pyridinoline (DPD), a marker of osteoclast activity, in 6-and 16-wk-old WT and TPH 1 −/− mice (Fig. 2C) . DPD/ creatinine ratios were dramatically reduced at both times in TPH 1 −/− mice (TPH 1 −/− vs. WT, −60% at 6 wk; −55% at 16 wk). Finally, to confirm in vivo that the decreased bone resorption observed in TPH 1 −/− mice was associated with a lack of 5-HT, the mutant animals were treated for 2 wk with 5-hydroxytryptophan (5-HTP) to override the TPH 1 invalidation. Consistent with the previous in vivo results, we found that the DPD ratio was in- , white bars) at 6 wk and were reduced at 16 wk. (C) Biochemical markers of bone formation. Serum osteocalcin levels were determined when the mice were 6 and 16 wk old. No significant difference was observed when the mice were 6 wk old, whereas a significant decrease in the osteocalcin level was observed when they were 16 wk old. (D) Proliferation was assessed after a 3-d culture period by BrdU incorporation in WT and TPH 1 −/− calvarial osteoblasts, and no difference was observed. (E) The capacity of WT and TPH 1 −/− primary osteoblasts to produce mineralized nodules was determined by alizarin staining after 18 d in culture, and no difference was observed. Data are shown as mean ± SEM; n = 8 mice per genotype. *P < 0.01 versus WT, **P < 0.001 versus WT, ***P < 0.0001 versus WT.
creased in mice treated with 5-HTP from the first week of treatment, and that the DPD ratio measured after 2 wk of treatment was in the same range as that measured in the 6-wk-old WT mice (Fig. 2D) .
To investigate the cell defects that lead to low bone resorption, we assessed osteoclastic differentiation from spleen cells and bone marrow macrophages in medium supplemented with M-CSF, RANKL, and dialyzed serum without 5-HT (Fig. 2E ). We showed that in TPH 1 −/− cultures, there were markedly fewer multinucleated TRAP-positive cells (−55%), assimilated to osteoclasts (OCLs), than in WT cultures. The osteoclast activity was determined by a pit assay on dentin slices. The pit area was lower in TPH 1 −/− than in WT cultures (Fig. 2F) . Furthermore, the pit area per osteoclast number was the same in both genotypes (Fig. 2F) . These findings suggest that 5-HT is involved in osteoclast differentiation, and that it does not affect osteoclast activity. In line with these functional findings, the expression of osteoclast markers (TRAP, Cathepsin K, and NFATc1) was significantly lower at the end of the culture in TPH 1 −/− than in WT, whereas RANK expression remained unchanged. These findings indicate that the number of precursors was the same in TPH 1 −/− and WT cultures (Fig. S1A) . Finally, to confirm that 5-HT plays a role during osteoclast differentiation, we treated TPH 1 −/− cell cultures with physiological concentrations of 5-HT (2.5, 5, 10, 20, and 50 nM). At concentrations from 5 nM 5-HT, and without any dose effect, the number of OCLs increased to reach WT levels (Fig. 2G) . Taken together, these findings suggest that an osteoclast defect was responsible for the decreased bone resorption in TPH 1 −/− mice.
Synthesis, Storage, and Reuptake of 5-HT in WT Osteoclast Precursors.
From the above data, and as TPH 1 −/− spleen and marrow macrophage cultures in the presence of RANKL have been shown to have reduced osteoclast differentiation capacity, we hypothesized that 5-HT was produced by the osteoclast precursors themselves. Indeed, we detected TPH 1 mRNA in WT cells, and its expression was blunted as the cells differentiated in the presence of RANKL (Fig. 3A) . RANKL significantly stimulated the expression of TPH 1 mRNA after exposure for 1 d (Fig. 3A) . We next investigated 5-HT production in spleen cell cultures after different culture times. We showed that 5-HT was produced in the cell lysate, was increased by RANKL, and then diminished toward the end of the culture period (Fig. 3B) . We went on to demonstrate that the 5-HT synthesized in WT osteoclast precursors is subsequently stored in intracellular granules by vesicular monoamine transporters (VMATs). We first showed that the expression of VMAT 1 and VMAT 2 mRNA at the end of the culture did not differ significantly in the two genotypes (Fig. S1B) . We treated the WT culture with reserpine, an inhibitor of both VMATs, and as in TPH 1 −/− cultures this induced a decrease in osteoclast differentiation, suggesting that intracellular storage of 5-HT plays a positive role in osteoclast differentiation (Fig. 3C ).
We next evaluated the possible reuptake of 5-HT by SERT, the plasma membrane serotonin transporter. Osteoclasts from WT mice expressed SERT (Fig. S1B) . To find out whether the inhibition of the cellular 5-HT influx played any role in the lower osteoclastogenesis, we treated the cells with paroxetine, a specific inhibitor of SERT. We observed that paroxetine markedly reduced osteoclast differentiation in WT osteoclast cultures, whereas it had no effect on osteoclast differentiation in TPH 1 −/− cultures (Fig. 3D ). These findings demonstrate that 5-HT was produced and stored in osteoclast precursor cells, and that 5-HT plays a significant role in osteoclast differentiation.
Serotonin Modulates Osteoclastic Differentiation via a Paracrine
Pathway. As 5-HT is produced locally, we thought it was worth investigating the expression of the different 5-HT receptors able to mediate a paracrine effect in osteoclast precursors. We evaluated the expression of the different 5-HT receptors by quantitative PCR at the end of WT cultures in the presence or absence of RANKL (Fig. S1C) . 5-HT 1A R and 5-HT 4 R mRNAs were not detected in WT spleen cell cultures. 5-HT 1B R was increased by the presence of RANKL after 5 d of culture. The level of 5-HT 2A R was the same in the presence or absence of RANKL. And, finally, 5-HT 2B R was significantly decreased in the presence of RANKL. To assess the functional role of these receptors in osteoclastogenesis, we next evaluated the effect of selective 5-HT receptor antagonists on these cultures. When WT spleen cells were treated with ritanserin, an inverse agonist of the 5-HT 2 receptor, we observed a significant decrease in osteoclast formation (Fig. 3E) . In contrast, RS127445, a specific 5-HT 2B R antagonist, did not produce any significant effect (Fig. 3E ), whereas at 25 nM, ketanserin, a specific 5-HT 2A R antagonist, induced effects similar to those of ritanserin (Fig. 3E) . Thus, 5-HT 2A R is the member of the 5-HT 2 family involved in osteoclast differentiation. In parallel, we treated WT cultures with SB224289, a 5-HT 1B receptor antagonist, and found that at 10 nM, this compound also had a significant effect on the number of osteoclasts (Fig. 3E) . These findings show that the 5-HT 1B and 5-HT 2A receptors were both implicated in osteoclast differentiation.
In Vivo Decrease in Bone Resorption in TPH 1 −/− Mice Is Due to an Intrinsic Osteoclast Defect. Our in vitro data support the existence of an intrinsic osteoclast defect in TPH 1 −/− mice. The low bone resorption observed in vivo in these mice could be directly related to a low level of serotonin in the bone microenvironment. To investigate this hypothesis in vivo, we carried out a series of bone marrow transplantations. Newborn WT and TPH 1 −/− mice were treated with busulfan and then transplanted with lineage-negative cells isolated from WT or TPH 1 −/− donors. As expected, 4 wk after transplantation, the DPD:creatinine ratio of TPH 1 −/− mice transplanted with TPH 1 −/− cells was lower than that of WT mice transplanted with WT cells. We then observed that the DPD: creatinine ratio in WT mice transplanted with TPH 1 −/− cells was lower than that of WT mice transplanted with WT cells and, finally, that the transplantation of WT cells into TPH 1 −/− mice rescued the DPD:creatinine ratio to the same level as that of WT mice transplanted with WT cells (Fig. 4A) . These DPD results were sustained 6 wk after transplantation. Furthermore, the histomorphometric study showed that both osteoclast surface area and osteoclast numbers decreased when mice were transplanted with TPH 1 −/− cells, and increased when transplantation was performed with WT cells (Fig. 4 B and C) . Taken together, these data support the existence of an osteoclast intrinsic defect that is responsible for the low bone resorption of TPH 1 −/− mice in vivo.
Discussion
The findings presented in this paper establish a function for local serotonin in bone remodeling. We were not able to show cellautonomous change in osteoblast function in the absence of serotonin, but we did find both in vivo and in vitro evidence that serotonin acts on the differentiation of monocytes/macrophages into osteoclasts via an autocrine/paracrine loop. We also show here that serotonin is synthesized by osteoclast precursors, and that bone resorption decreases in the absence of serotonin synthesis by osteoclast precursors. We were also able to demonstrate by in vivo and in vitro rescues that serotonin is indeed responsible for the low bone resorption in mutant mice and, using marrow transplantation, that this low bone resorption is cell-autonomous in TPH 1 −/− mice. We therefore conclude that serotonin has complex physiological actions in bone, as in other tissues (4).
Our findings complete and can reconcile those of previous studies of serotonin in bone. In contrast to a present study, Yadav and colleagues (15) analyzed a mouse line with a specific inactivation of TPH 1 affecting either the gut or the osteoblasts, and could not, therefore, detect any specific function of 5-HT produced by osteoclasts. Cui and colleagues (17) have shown that TPH 1 −/− mice had no change in BMD at 4 and 6 mo, but did not investigate bone remodeling. Here, in accordance with the Cui et al. data, we show an unchanged BMD at 16 wk. However, when deep phenotyping was performed, we observed that this unchanged BMD at 16 wk in TPH 1 −/− mice was associated with a decrease in both bone resorption and formation at that time (Fig. 1) . Interestingly, although low bone resorption was observed in both growing and mature mice, high trabecular bone volume was only observed in growing TPH 1 −/− mice. Although gut is the main organ responsible for peripheral 5-HT synthesis, several other peripheral tissues have recently been demonstrated to be 5-HT producers with important physiological roles, even though the amounts of serotonin measured in these tissues were far lower than those in the gut (12) (13) (14) 23) . Serotonin was synthesized by osteoclast precursors, as we could detect TPH 1 mRNA expression and serotonin at different times during the cultures with RANKL. The level of serotonin present in the osteoclast precursors was in the same range as that necessary to rescue osteoclast differentiation in TPH 1 −/− cultures. The synthesis of serotonin was increased by RANKL during the first day, and then decreased as the cells differentiated. In these experiments, we used primary spleen cell cultures, composed mainly of monocytes/macrophages, cultured with M-CSF and RANKL. These cells were engaged in osteoclast differentiation, and we show here that local serotonin synthesis was increased by RANKL in osteoclast precursors. Interestingly, it has recently been shown that the bone marrow of TPH 1 −/− mice contains fewer nucleated cells (24) . Although only erythropoiesis was studied, it is not impossible that in TPH 1 −/− mice the myeloid lineage could also have been altered, and that the reduced osteoclast differentiation we observed from spleen and bone marrow monocytes/macrophages was already present in earlier precursors.
It had previously been shown that serotonin can act on the cells of the immune system (7, 25) . Battaglino and colleagues demonstrated the presence of serotonin receptors 1B, 2B, and 4 in the RAW264.7 cell line, induced by M-CSF and RANKL in the osteoclast lineage (26) . This is why we focused on the 1, 2, and 4 families of 5-HT receptors. Using RT-PCR, we demonstrated that the 5-HT 1B , 5-HT 2A , and 5-HT 2B receptors are expressed in osteoclast precursors of the monocyte/macrophage lineage, whereas 5-HT 1A and 5-HT 4 receptors were not detected. We also demonstrated increased 5-HT 1B R expression after induction with RANKL, which suggests that this receptor is associated with the differentiation of the osteoclast precursors. In contrast, the expression of 5-HT 2A R did not change in the presence of RANKL, which suggests that it acts before the osteoclast lineage begins. Finally, as the monocytes differentiated into osteoclasts, the expression of 5-HT 2B R decreased. We tested the functional role of these receptors by specific pharmacological inhibitors, and were able to show that two of them (5-HT 1B R and 5-HT 2A R) could mediate the action of serotonin on osteoclast differentiation. These serotonin receptors are known to be implicated in the regulation of intracellular calcium concentration via several pathways (27, 28) . Furthermore, during osteoclast differentiation, intracellular calcium signaling activates NFATc1, the master regulator of osteoclastogenesis (29, 30) . We can, therefore, hypothesize that these two serotonin receptors could be implicated in osteoclast differentiation.
To maintain healthy bone tissue, osteoclastic bone resorption and osteoblast-mediated bone formation have to be tightly coupled. As low osteoclastic bone resorption was observed in mice lacking peripheral serotonin, we expected to find reduced bone formation. However, surprisingly, bone formation was maintained in 6-wk-old TPH 1 −/− mice, resulting in an increase in osteoclast number per bone surface (OCs/BS) and the osteoclast number. These parameters showed a similar pattern to the DPD ratio: When WT cells were transplanted into TPH 1 −/− mice, we observed an increase in the bone resorption parameter, and when TPH 1 −/− cells were transplanted into WT mice, we found that rescue of bone resorption occurred. Data are shown as mean ± SEM; n = 5-8 mice per genotype. *P < 0.05 versus WT, **P < 0.005 versus WT, ***P < 0.0005 versus WT.
trabecular bone volume at this age. However, in mature 16-wk-old mice, we observed that low bone resorption was accompanied by the expected low bone formation that may have resulted from cellular coupling, as no intrinsic osteoblast defect could be demonstrated in TPH 1 −/− mice. Osteoclasts are now recognized as having a direct key role in bone remodeling. More recently, it has been revealed that osteoclasts can directly release soluble factors, and it is suspected that they may be involved in the coupling between resorption and formation (31, 32) . We can therefore speculate that serotonin secreted by osteoclast precursors could not only play a role in osteoclast differentiation but also act on neighboring osteoblasts via a paracrine mechanism. Furthermore, circulating serotonin could also act on osteoblasts. However, the role of the physiological concentration of serotonin in osteoblast proliferation remains to be elucidated, as so far only pharmacological concentrations have been investigated (15) .
In summary, our results show that physiological levels of serotonin enhance osteoclastic resorption. We also demonstrate that RANKL enhances the expression of TPH 1 and the synthesis of serotonin by the osteoclasts themselves. When RANKL is produced by osteoblasts, serotonin synthesized by osteoclast precursors could act synergistically with RANKL signaling and further increase osteoclast differentiation (Fig. S2 ). In conclusion, we propose that serotonin can increase osteoclast differentiation via the autocrine/paracrine pathway. These findings are of importance with regard to the role of serotonin in bone remodeling.
Materials and Methods
Skeletal Phenotyping. The generation of mice lacking TPH 1 on an Sv129 background has been reported previously (10) . All of the experiments were approved by the Ethics Committee of Paris Diderot University, and complied fully with French government animal welfare policy. Histomorphometry was carried out as described previously (21) Statistics. Results are expressed as mean ± SEM. Statistical analyses were carried out by the StatView analysis program (SAS Institute, Cary, NC), using a two-way ANOVA to compare differences between genotypes. P values less than 0.01 were considered to be significant. *P < 0.01 versus WT, **P < 0.001 versus WT, ***P < 0.0001 versus WT. For additional details, see SI Materials and Methods.
